enGene Holdings Inc ENGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
-
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
-
enGene to Participate in Upcoming Investor Conferences
-
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
-
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 33
- Website
- https://www.engene.com
Comparables
Valuation
|
Metric
|
ENGN
|
PYC
|
FULC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.27 | 9.85 | 0.81 |
Price/Sales | — | — | 2.75 |
Price/Cash Flow | — | — | — |
Price/Earnings
ENGN
PYC
FULC
Financial Strength
|
Metric
|
ENGN
|
PYC
|
FULC
|
|---|---|---|---|
Quick Ratio | 19.16 | 3.95 | 21.84 |
Current Ratio | 19.52 | 3.99 | 22.07 |
Interest Coverage | −39.66 | — | — |
Quick Ratio
ENGN
PYC
FULC
Profitability
|
Metric
|
ENGN
|
PYC
|
FULC
|
|---|---|---|---|
Return on Assets (Normalized) | −28.25% | — | −1.76% |
Return on Equity (Normalized) | −42.14% | — | −1.91% |
Return on Invested Capital (Normalized) | −33.08% | — | −1.83% |
Return on Assets
ENGN
PYC
FULC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bxxdywzh | Dwh | $524.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ztdrjtxtn | Gyprw | $120.0 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wnkglztpd | Jbfwd | $115.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gjnklcgd | Xbhwzf | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Wwydldcz | Bjmhv | $32.4 Bil | |||
| BioNTech SE ADR
BNTX
| Zbmnvzxxb | Dyp | $28.2 Bil | |||
| Moderna Inc
MRNA
| Hsllxdkxc | Znz | $25.7 Bil | |||
| United Therapeutics Corp
UTHR
| Qptrkxkb | Dyfk | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kytqggm | Ptlpw | $13.4 Bil | |||
| Incyte Corp
INCY
| Xfxvcjzvd | Nwkvwvt | $12.7 Bil |
United States